Sector
PharmaceuticalsOpen
₹480Prev. Close
₹480.3Turnover(Lac.)
₹5,395.56Day's High
₹490.85Day's Low
₹478.2552 Week's High
₹72152 Week's Low
₹422Book Value
₹141.43Face Value
₹1Mkt Cap (₹ Cr.)
11,820.37P/E
39.84EPS
12.22Divi. Yield
0.3115 May 2024
12:00 AM
Dividend
Dividend Amount: 1.5
Record Date: 30 Jul, 2024
15 May 2024
12:00 AM
BookCloser
7 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
15 May 2024
12:00 AM
AGM
Announcement Date: 15 May, 2024
The five-day inspection ran from June 16 to June 20, 2025
The firm’s net debt fell by ₹136 crore to ₹706.1 crore, with a comfortable net debt-to-EBITDA at 0.75x
The pharma company caters to various international markets, reinforcing its position as a key player in the pharmaceutical industry.
Granules India, maintaining that it fully intends to respond in the time period allowed, as well as requesting a meeting with the FDA to show progress made in compliance, has taken care to make this clear as well.
The inspection covered Active Pharmaceutical Ingredients (APIs) and Finished Dosages (FDs) for oncology and non-oncology segments, underscoring the plant’s adherence to high manufacturing standards.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 24.24 | 24.2 | 24.8 | 24.77 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 3,086.71 | 2,675.26 | 2,505.86 | 2,137.85 |
Net Worth | 3,110.95 | 2,699.46 | 2,530.66 | 2,162.62 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 3,238.43 | 3,134.98 | 2,309.92 | 1,646.64 |
yoy growth (%) | 3.29 | 35.71 | 40.28 | 22.02 |
Raw materials | -1,757.74 | -1,509.64 | -1,221.98 | -903.09 |
As % of sales | 54.27 | 48.15 | 52.9 | 54.84 |
Employee costs | -282.79 | -318.25 | -192.51 | -147.92 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 519.64 | 732.87 | 391.9 | 208.45 |
Depreciation | -126.16 | -118.45 | -101.82 | -75.91 |
Tax paid | -133.13 | -180.08 | -108.95 | -69.29 |
Working capital | 350.84 | 159.58 | 230.57 | 276.19 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 3.29 | 35.71 | 40.28 | 22.02 |
Op profit growth | -25.16 | 74.31 | 68.34 | -0.76 |
EBIT growth | -29.16 | 80.68 | 73.48 | 1 |
Net profit growth | -30.07 | 24.48 | 219.1 | -2.56 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 4,455.97 | 4,490.16 | 4,511.92 | 3,764.92 | 3,237.54 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 4,455.97 | 4,490.16 | 4,511.92 | 3,764.92 | 3,237.54 |
Other Operating Income | 25.64 | 16.21 | 0 | 0 | 0 |
Other Income | 43.67 | 4.4 | 13.78 | 17.61 | 26.88 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.6 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.1 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,164 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
C Krishna Prasad
Executive Director
Harsha Chigurupati
Executive Director
Uma Devi Chigurupati
Non-Exec & Non-Independent Dir
K B Sankara Rao
Company Sec. & Compli. Officer
Chaitanya Tummala
Non-Exec. & Independent Dir.
Arun Sawhney
Independent Director
Saumen Chakraborty
Independent Director
Sucharita Rao Palepu
Joint Managing Director & CEO
KVS Ram Rao
Independent Director
Kapil Mehan
Independent Director
Rajiv Kakodkar
Executive Director
Priyanka
Independent Director
S Ravi
Second Floor Block III,
My Home Hub Madhapur,
Telangana - 500081
Tel: 91-40-66760000
Website: http://www.granulesindia.com
Email: investorrelations@granulesindia.com; mail@granules
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Granules India Limited is a large-scale vertically integrated company founded in March, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Fin...
Read More
Reports by Granules India Ltd
What is the Granules India Ltd share price today?
What is the Market Cap of Granules India Ltd?
What is the PE and PB ratio of Granules India Ltd?
What is the 52 Week High and Low of Granules India Ltd?
What is the CAGR of Granules India Ltd?
What is the shareholding pattern of Granules India Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
